勇敢之心生物
BRVE
18.71
-0.84
-4.30%
勇敢之心生物
US · BRVE
#2845 按市值排名
上市于 2026
18.71
-0.84
-4.30%
实时 - 追踪5344个代码 - 心跳于534秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了7家。
- 机构持股总比例上升了65.9个百分点。
机构持股
- 机构持股比例
- 68.93% +65.91pp
- 机构数量
- 8 +7
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund59.85%
Individual/Insider15.11%
Public Company9.00%
Other15.96%
主要股东 截至 2026-08-07
Forbion Capital Partners B.V.
26.47% · 21.83M 股
OrbiMed Advisors LLC
14.77% · 12.18M 股
Andreessen Horowitz LLC
12.41% · 10.23M 股
Travis Murdoch
10.11% · 8.33M 股
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
9.00% · 7.42M 股
Frazier Life Sciences Management, LP
6.19% · 5.11M 股
Jason Coloma
1.71% · 1.10M 股
David Malek
1.23% · 1.01M 股
James Rickey
0.85% · 703.58K 股
Christopher Viehbacher
0.74% · 609.52K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪34份申报 · 22次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Forbion Capital Partners B.V. | -- | 26.47% |
| OrbiMed Advisors LLC | -- | 14.77% |
| Andreessen Horowitz LLC | -- | 12.41% |
| Travis Murdoch | Chief Executive Officer | 10.11% |
| Jason Coloma | Director | 1.71% |
| David Malek | Director | 1.23% |
| James Rickey | Chief Financial Officer | 0.85% |
| Christopher Viehbacher | Independent Chairperson | 0.74% |
| Michele Anderson | Chief Development Officer | 0.40% |
| David Lubner | Independent Director | 0.07% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-06 | OrbiMed Advisors LLC | -- | Private Acquisition | +1,940,000 | $18.00 |
| 2026-08-06 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +9,132,420 | -- |
| 2026-08-06 | David Lubner | Independent Director | Private Acquisition | +55,555 | $18.00 |
| 2026-08-06 | Christopher Viehbacher | Independent Chairperson | Private Acquisition | +83,333 | $18.00 |
| 2026-08-06 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Derivative Exercise and Retained | +7,420,091 | -- |
| 2026-08-06 | Forbion Capital Partners B.V. | -- | Private Acquisition | +3,600,000 | $18.00 |
| 2026-08-06 | Forbion Capital Partners B.V. | -- | Derivative Exercise and Retained | +17,123,287 | -- |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Private Acquisition | +1,100,000 | $18.00 |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Derivative Exercise and Retained | +9,132,420 | -- |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-06 | David Malek | Director | Private Acquisition | +4,166 | $18.00 |
| 2026-08-06 | James Rickey | Chief Financial Officer | Private Acquisition | +27,777 | $18.00 |
| 2026-08-06 | Michele Anderson | Chief Development Officer | Private Acquisition | +1,111 | $18.00 |
| 2026-08-06 | Travis Murdoch | Chief Executive Officer | Private Acquisition | +83,333 | $18.00 |
| 2026-08-04 | OrbiMed Advisors LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | David Lubner | Independent Director | Other Derivative Acquisition | +60,000 | $18.00 |
| 2026-08-04 | Christopher Viehbacher | Independent Chairperson | Other Derivative Acquisition | +30,000 | $18.00 |
| 2026-08-04 | Christopher Viehbacher | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | Erez Chimovits | Independent Director | Other Derivative Acquisition | +30,000 | $18.00 |
| 2026-08-04 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
勇敢之心生物 讨论区 0 条评论